Underlying growth, reported sales decline
Consolidated revenue -1.5% YoY despite double-digit business growth excluding North American lenalidomide.
Watch: WATCH — normalize the post-lenalidomide earnings base.
Home / Research / Dr. Reddy's Laboratories Limited
Underlying growth, reported sales decline
https://www.bseindia.com/xml-data/corpfiling/AttachHis/3787a62c-6056-45bf-a566-3851ca03f88c.pdf
https://www.bseindia.com/xml-data/corpfiling/AttachHis/3787a62c-6056-45bf-a566-3851ca03f88c.pdf
https://www.bseindia.com/xml-data/corpfiling/AttachHis/3787a62c-6056-45bf-a566-3851ca03f88c.pdf
https://www.bseindia.com/xml-data/corpfiling/AttachHis/3787a62c-6056-45bf-a566-3851ca03f88c.pdf
Consolidated revenue -1.5% YoY despite double-digit business growth excluding North American lenalidomide.
Watch: WATCH — normalize the post-lenalidomide earnings base.
Prior-quarter semaglutide inventory provisions distort sequential improvement.
Watch: Separate API remediation from recurring margin.
Gross margin gained 562 bps sequentially but remained 254 bps below Q2 FY26.
Watch: Track product-mix and remediation effects.
Q2 R&D spend of ₹524cr, about 6% of reported revenue.
Watch: Assess future launch output against spending.
SAGE PRO | Q2 FY2027, quarter ended 30 September 2026 | 17 November 2026 | NSE: DRREDDY Research stance: WATCH — underlying product momentum is encouraging, but the decline in lenalidomide and execution risks matter. This is a seven-chapter company-specific investor report, built from the already accepted October 2026 issuer presentation and earnings-call evidence. Figures are consolidated IFRS and ₹ crore unless stated otherwise.
What is working. Excluding North American lenalidomide, the company described double-digit growth in its underlying businesses, supported by product launches in India, North America and emerging markets. Q2 FY27 revenue was ₹8,671 crore, up approximately 7% sequentially, but down 1.5% year-on-year. EBITDA was ₹1,783 crore, a 20.6% margin.
Key takeaways
What the valuation demands. A defensible valuation requires the sustainable post-lenalidomide profit base, regulatory execution, biosimilar/product economics and a current price reference. No unverified numerical target is published.
| Issuer-reported Q2 FY27 measure | Figure | Comparison or basis |
|---|---|---|
| Consolidated revenue | ₹8,671 crore | -1.5% YoY, approximately +7.4% QoQ |
| EBITDA incl. other income | ₹1,783 crore | Margin 20.6%, -24% YoY, +77% QoQ |
| Profit before tax | ₹1,228 crore | Margin 14.2%, -33% YoY, +122% QoQ |
| PAT attributable to equity shareholders | ₹925 crore | Margin 10.7%, -36% YoY, +109% QoQ |
| Gross profit margin | 52.1% | +562 bps QoQ, -254 bps YoY |
| R&D expense | ₹524 crore | Approximately 6% of revenue |
| SG&A | ₹2,808 crore | Approximately 32% of revenue |
| Quarter capex cash outflow | ₹186 crore | Management call figure |
| Net cash surplus, 30 Sep 2026 | ₹2,502 crore | Management-reported, not enterprise valuation |
Why it matters: The contrast between a declining reported YoY P&L and growing underlying business is the central research question. Model both rather than treating the adjusted base as reported results.
---
Dr. Reddy's is transitioning away from exceptional revenues on certain North American generic products toward a broader portfolio of branded generics, complex generics, biosimilars, new partnerships and CDMO services. The logic is attractive: success across more molecules and markets would reduce dependence on a single unusually profitable asset. But volume growth in replacement products can have lower margins, greater regulatory risk or higher development expenditure.
Key takeaways
Bull hypothesis: India, emerging markets, new North American products and selected complex generics grow fast enough to absorb lenalidomide's fade while efficiencies stabilize gross margin.
Counter-hypothesis: The company wins revenue in new therapies but lower contribution per sale, generic pricing competition and regulatory remediation absorb returns.
The key analytical question is whether every rupee of replacement revenue can generate an appropriate return after R&D, regulatory costs, manufacturing investment and working capital. As of Q2 FY27, the report documents an encouraging commercial pipeline but does not assume every announced launch reaches scale.
Next observable proof: ongoing revenue and margin excluding lenalidomide, product-level approvals versus commercial launches, India growth on a comparable basis, and normalized operating cash conversion.
---
The 23 October 2026 Q2 presentation is explicit: consolidated revenue was ₹8,671 crore, 1.5% below the year-earlier period but about 7% higher sequentially. EBITDA including other income reached ₹1,783 crore at a 20.6% margin; attributable PAT was ₹925 crore at 10.7%. These are the reported IFRS-group quarter figures; they are not a nine-month run rate.
Key takeaways
Q1 FY27 also carried about ₹240 crore of inventory and related provisions connected with semaglutide API issues. That makes Q1 a poor clean denominator for evaluating underlying momentum.
The CFO described a 52.1% consolidated gross profit margin, up 562 basis points sequentially and down 254 basis points from Q2 FY26. The year-on-year decline was linked mainly to lower lenalidomide sales; Q1 margins had also been affected by semaglutide-related inventory costs. The correct model should treat the product mix, one-off provisions and future replacement assets separately.
SG&A was ₹2,808 crore, or around 32% of revenues, reflecting personnel increments, FX and freight pressures. R&D was ₹524 crore, or 6% of revenues, 16% below the year-earlier quarter. A lower R&D burden supports near-term margin but should not be treated as permanent savings if the development pipeline must be replenished.
Why it matters: Any investment forecast must independently consider the loss of a high-margin North American product, the durability of core growth, the treatment of API remediation costs and the medium-term R&D burden. A simple revenue CAGR applied to the current EBITDA margin is insufficient.
---
North America. The presentation identifies ₹2,489 crore of North American global-generics revenue for Q2 FY27 and a significant reported YoY drag as lenalidomide sales step down. Management said the underlying business excluding lenalidomide grew in double digits. North American generic competition can compress selling prices rapidly, and approval-driven launches make revenue uneven. Watch the launch cadence, price erosion, share sustainability and treatment of product-specific provisions.
Key takeaways
India. The business is a strategic base for the company and a potential launch market for partnered vaccines and biosimilars. Management reported progress on product partnerships including the Takeda dengue vaccine, with a planned private-market introduction in H1 calendar 2027. This is a dated commercial ambition, not Q2 realized vaccine revenue.
Emerging markets. The company described double-digit underlying expansion and approvals for generic semaglutide in multiple jurisdictions. Regulatory authorization, market access and supply execution are separate steps; approvals alone do not establish contribution margin or market share.
CDMO / Aurigene. The presentation notes Aurigene Pharmaceutical Services passing US$100 million in revenue over the 12 months ending September 2026. A 12-month revenue threshold is not a quarterly consolidated-profit contribution. Contract mix, customer concentration, capital intensity and profitability require separate evidence.
Why it matters: The replacement portfolio is better diversified than a single high-margin molecule but may be less profitable per unit of revenue. Sustainable cash generation, rather than the count of product launches, should settle the thesis.
---
The CFO reported ₹14,650 crore of operating working capital at 30 September 2026, approximately ₹297 crore above the June date. Working-capital growth can accompany geographic expansion and inventory requirements, but poor inventory turnover can also trap cash.
Key takeaways
Dr. Reddy's reported a ₹2,502 crore net cash surplus at quarter-end. That supports financing flexibility for launches, remediation and development, but there is no basis here for adding the entire figure to a valuation without considering the enterprise balance-sheet bridge, working capital and capital deployment.
The call also discussed foreign-currency hedge positions. Currency swings can affect reported margin and translation between rupees and foreign operations. A properly controlled comparison should separate local-currency sales, forex effects and customer pricing where the company discloses them.
Investment implication: Net cash is a useful buffer against product and remediation uncertainty, not evidence that the future pipeline will be self-funding at any rate of spend. Monitor working capital, capex, cash flow definitions, cash tied in product launches and unforeseen regulatory expenses.
---
In its October call and Q2 presentation, management reiterated a long-term focus on double-digit underlying growth and sustainable margins. These objectives are directional, not the same as a guarantee of reported double-digit revenue growth during lenalidomide runoff.
Key takeaways
Biosimilars. The company reported a USFDA approval for a rituximab biosimilar and an India launch of a nivolumab biosimilar. These are strategically important but commercialization will depend on channel access, contracts, production and economics. Pipeline valuation should not treat approval as full market penetration.
Partnerships. Takeda's dengue-vaccine partnership, Gilead's HIV-prevention collaboration and other assets expand strategic optionality. Timelines and economics are uneven; an agreement, expected launch and realized cash earnings are not equivalent.
Quality and manufacturing. The presentation includes Form 483 observations across facilities and follow-up responses. These are genuine execution risks, not trivial administrative footnotes. Track closure status and any capacity or product supply effects before underwriting recovery.
Analyst questions and response themes. Management faced questions about profitability normalization, U.S. product dynamics, regulatory issues and the development portfolio. The investment-relevant response is the distinction between underlying commercial strength and actual reported EBITDA or cash realization; neither bullish commentary nor the count of regulatory filings substitutes for observed results.
Next-quarter dashboard: regulatory follow-up, semaglutide commercial recovery, lenalidomide decline, geographic margin mix, working-capital conversion and actual biosimilar shipments.
---
| Risk | Mechanism | Watch |
|---|---|---|
| Lenalidomide decline | Reduction of an exceptional higher-margin revenue stream | Reported North America revenue and product-mix-driven gross margin |
| Pricing erosion | Generic drug competition can overwhelm volume growth | Realized price/mix and local-currency growth |
| Quality remediation | Batch or site issues lead to write-offs, cost and launch delays | Closure/response on manufacturing observations |
| Launch execution | Approvals do not guarantee scalable market access | Shipments, contracts and real contribution profit |
| R&D productivity | Development expenditure may not monetize | Pipeline stage, R&D spend and eventual launches |
| Working-capital demands | Inventory or receivables absorb cash | Working capital, cash conversion and capex |
| FX and geography | Rupee translation and different market margins | Constant-currency trends and regional contribution |
Key takeaways
Base case: core sales grow but reported earnings remain restrained by lower legacy-product contribution, uneven geography and ongoing development investment. Sequential improvement occurs without a rapid return to the prior year's profit mix.
Bear case: regulatory issues persist, newer launches miss revenue or margin targets, lenalidomide falls faster than replacement profits ramp, and inventory or pricing losses weaken cash conversion.
These are conditional operating cases, not ₹/share valuations. We do not invent a fair value or peer multiple without comparable and dated inputs. The risks are important regardless of the headline AI score.
What breaks the constructive thesis: sustained reported gross margin weakness, deterioration in net cash, persistent unresolved quality observations, or replacement sales failing to produce positive incremental profit.
---
What to verify next. Prioritize the next quarter's reported IFRS group P&L over a selective adjusted base. Separately record North American lenalidomide runoff and growth in the remaining North American portfolio. Compare the gross margin to Q2's 52.1% and preserve the difference between EBITDA with other income and earnings before tax.
Key takeaways
Execution is the third test. Track manufacturing observations and their actual closures, semaglutide product shipments, approved biosimilar revenues and profitability, and partners' commercialization dates. The count of approvals without realized sales is not sufficient for valuation.
[1] Dr. Reddy's Q2 FY2027 investor presentation, issued 23 October 2026, document 11858, quarter ended 30 September 2026. It reports consolidated IFRS group figures and the product/region context. Original filing: https://www.bseindia.com/xml-data/corpfiling/AttachHis/3787a62c-6056-45bf-a566-3851ca03f88c.pdf.
[2] Dr. Reddy's Q2 FY2027 earnings conference call, held 23 October 2026, document 73675. The full original is stored and accepted for analysis within Sage PRO. Issuer link: The company's redistribution restrictions are respected here: analysis is paraphrased rather than reproducing the transcript.
Simple limitation: Based on company disclosures; uncertain future product earnings and valuation are not assumed.
Glossary. IFRS: international financial reporting standards. EBITDA: earnings before interest, tax, depreciation and amortization; here the issuer includes other income. API: active pharmaceutical ingredient. CDMO: contract development and manufacturing organization. YoY: versus the same quarter one year earlier. QoQ: versus the preceding quarter. Net cash surplus: management-defined net liquidity after specified borrowing offsets, not always free cash.
Bottom line: The underlying franchise appears healthier than the reported year-on-year revenue line suggests. Whether that merits a rerating depends on replacing lenalidomide contribution, resolving quality risks and turning launches into durable cash profits. No unsupported target is offered.
https://www.bseindia.com/xml-data/corpfiling/AttachHis/3787a62c-6056-45bf-a566-3851ca03f88c.pdf
This is dated research, not a live market quote. Scenarios and historical performance are not guarantees.